NCT05702827View on ClinicalTrials.gov

Use of a Dual-agent Local Analgesic (Bupivacaine-meloxicam) for Abdominal Incisions in Patients Undergoing Retropubic Mid-urethral Sling Surgery

PHASE3CompletedINTERVENTIONAL
Enrollment

148

Participants

Timeline

Start Date

January 23, 2023

Primary Completion Date

March 22, 2024

Study Completion Date

April 18, 2024

Conditions
Stress Urinary IncontinenceSurgical IncisionPain Vulva
Interventions
DRUG

Bupivacaine-Meloxicam

All patients will receive standard of care but the study arm will also receive Bupivacaine-Meloxicam in addition.

Trial Locations (2)

45220

Cincinnati Urogynecology Associates, Cincinnati

Trihealth (Good Samaritan Hospital, Bethesda North Hospital), Cincinnati

All Listed Sponsors
lead

TriHealth Inc.

OTHER